Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

It "builds on Hims & Hers’ existing suite of weight loss solutions and provides access to all dose strengths of Wegovy in a high-quality pen for self-pay patients," Hims & Hers said.

Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides ...

Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo ...

This new offering builds on Hims & Hers’ existing suite of weight loss solutions and provides access to all dose strengths of Wegovy® in a high-quality pen for self-pay patients. The platform ...

Regardless, Hims & Hers showed its business is more than just about weight-loss drugs and its products and services are proving popular among consumers looking for lower cost healthcare solutions.

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Quantitative Momentum Investor model based on the ...

Hims & Hers Health is up 112% since the beginning of the year, but at $53.35 per share, it is still trading 22.4% below its 52-week high of $68.74 from February 2025.